Avanos Medical, Inc. (AVNS)
NYSE: AVNS · Real-Time Price · USD
24.80
+0.04 (0.16%)
May 29, 2026, 4:00 PM EDT - Market closed
Avanos Medical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 715.9 | 701.2 | 687.8 | 673.3 | 684.1 | 587 | |
Revenue Growth (YoY) | 3.87% | 1.95% | 2.15% | -1.58% | 16.54% | -17.88% |
Cost of Revenue | 357.6 | 347.3 | 306.5 | 293.6 | 289.9 | 287.8 |
Gross Profit | 358.3 | 353.9 | 381.3 | 379.7 | 394.2 | 299.2 |
Selling, General & Admin | 317.6 | 315.6 | 318.5 | 335 | 326.5 | 285.3 |
Research & Development | 23.1 | 23.3 | 26.2 | 27.2 | 29.2 | 30.6 |
Other Operating Expenses | 78.1 | 77.4 | 440.6 | -13.3 | -3 | - |
Total Operating Expenses | 418.8 | 416.3 | 785.3 | 348.9 | 352.7 | 315.9 |
Operating Income | -63 | -61.6 | -396.2 | 4.2 | 35.5 | -39 |
Interest Income | 1.9 | 3.2 | 5.1 | 2.9 | 1.2 | 0.2 |
Interest Expense | -7.2 | -7.8 | -12.2 | -15 | -10 | -3.3 |
Other Non-Operating Income (Expense) | -4.7 | - | - | - | - | -22.3 |
Total Non-Operating Income (Expense) | -10 | -4.6 | -7.1 | -12.1 | -8.8 | -25.4 |
Pretax Income | -68.3 | -66.2 | -403.3 | -7.9 | 26.7 | -42.1 |
Provision for Income Taxes | 3.6 | 6.7 | -17 | 2 | 5.2 | -11.2 |
Net Income | 84.6 | 72.9 | 392.1 | 61.8 | -50.5 | -6.3 |
Earnings From Discontinued Operations | - | - | -5.8 | -51.9 | 29 | 37.2 |
Net Income to Common | 84.6 | 72.9 | 392.1 | 61.8 | -50.5 | -6.3 |
Net Income Growth | -78.73% | -81.41% | 534.47% | - | - | - |
Shares Outstanding (Basic) | 46 | 46 | 46 | 47 | 47 | 48 |
Shares Outstanding (Diluted) | 47 | 46 | 46 | 47 | 47 | 49 |
Shares Change (YoY) | 0.48% | 0.65% | -1.29% | -1.48% | -2.67% | 1.67% |
EPS (Basic) | -1.61 | -1.57 | -8.53 | -1.32 | 1.08 | -0.64 |
EPS (Diluted) | -1.61 | -1.57 | -8.53 | -1.32 | 1.07 | -0.64 |
Shares Outstanding | 46.67 | 46.46 | 45.96 | 46.17 | 46.53 | 48.21 |
Free Cash Flow | 7.5 | 43.1 | 82.9 | 14.6 | 71.6 | 66.3 |
Free Cash Flow Growth | -82.60% | -48.01% | 467.81% | -79.61% | 7.99% | - |
Free Cash Flow Per Share | 0.16 | 0.93 | 1.80 | 0.31 | 1.51 | 1.36 |
Gross Margin | 50.05% | 50.47% | 55.44% | 56.39% | 57.62% | 50.97% |
Operating Margin | -8.80% | -8.78% | -57.60% | 0.62% | 5.19% | -6.64% |
Profit Margin | -11.10% | -10.40% | -56.16% | -1.47% | 3.14% | -5.26% |
FCF Margin | 1.05% | 6.15% | 12.05% | 2.17% | 10.47% | 11.29% |
EBITDA | -23.5 | -22.7 | -350.7 | 50.3 | 83.2 | -0.7 |
EBITDA Margin | -3.28% | -3.24% | -50.99% | 7.47% | 12.16% | -0.12% |
EBIT | -63 | -61.6 | -396.2 | 4.2 | 35.5 | -39 |
EBIT Margin | -8.80% | -8.78% | -57.60% | 0.62% | 5.19% | -6.64% |
Effective Tax Rate | -5.27% | -10.12% | 4.22% | -25.32% | 19.48% | 26.60% |